Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T82943
|
|||||
Target Name |
microRNA hsa-miR-17 (MIR17)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Autosomal dominant polycystic kidney disease [ICD-11: GB81] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | RGLS4326 | Drug Info | Phase 1 | Autosomal dominant polycystic kidney disease | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | RGLS4326 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. | |||||
REF 2 | ClinicalTrials.gov (NCT04536688) A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.